CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Cixutumumab +1 morebiological
Likely dose
Cixutumumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01413191
NCT01413191Phase 2Completed
CompareCT.gov

Phase II Study of IMC-A12 in Metastatic Uveal Melanoma

National Cancer Institute (NCI)·interventional·Posted Aug 10, 2011·Updated Feb 19, 2020

In Brief

A Phase 2 clinical trial evaluating Cixutumumab and Laboratory biomarker analysis for Ciliary Body and Choroid Melanoma, Medium/Large Size and 5 related conditions. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCiliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 10, 2011
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.9 years ago

Interventions

Cixutumumabbiological

10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks

Laboratory biomarker analysisother

Correlative studies